DCAF16 protein: an E3 ligase substrate receptor for covalent targeted degradation and a modular drug design platform

Author: Senior Product Manager of UA Views：6

This article systematically elaborates on the molecular characteristics and biological functions of DCAF16, describing its structural localization and tissue expression features as a substrate receptor of the CUL4-DDB1 E3 ubiquitin ligase complex, analyzing its molecular mechanisms for recruiting novel substrates such as BRD4, SMARCA2/4, CDK4/6, and the androgen receptor through covalent modification of cysteine residues, and exploring its modular application value in the design of PROTACs and molecular glue degraders as well as its translational potential as a therapeutic target for triple-negative breast cancer.

Recent Advances
Product Information

Recent Advances

DCAF16 Protein: An E3 Ligase Substrate Receptor for Covalent Targeted Degradation and a Modular Drug Design Platform

Brief Description: This article focuses on the molecular characteristics and biological functions of DCAF16, systematically elaborating its structural localization and tissue expression features as a substrate receptor of the CUL4-DDB1 E3 ubiquitin ligase complex, analyzing the molecular mechanism by which it recruits neosubstrates such as BRD4, SMARCA2/4, CDK4/6, and the androgen receptor through covalent modification of cysteine residues, and discussing its modular application value in the design of PROTACs and molecular glue degraders as well as its translational potential as a therapeutic target for triple-negative breast cancer.

I. Molecular characteristics of DCAF16 and its localization within the E3 ligase complex.

DCAF16 is the substrate recognition component of the CUL4-DDB1 E3 ubiquitin ligase complex, mediating the degradation of target proteins via the ubiquitin-proteasome system. Human DCAF16 is a protein composed of 216 amino acids, highly conserved in mammals but absent in rodents. Sequence analysis predicts that it may be a nuclear protein, while immunohistochemical detection shows that DCAF16 is mainly expressed in the cytoplasm of epithelial tissues, including thyroid follicles, prostate and gastric gland epithelium, as well as bronchial, intestinal, and hepatocellular epithelium. Unlike most DCAF family members, DCAF16 does not contain a canonical WD40 propeller structure, but is instead a relatively unstable protein predicted to be largely unstructured. This structural uniqueness precisely provides the structural basis for covalent modification of its cysteine-rich substrate-binding interface on the surface.

II. Molecular mechanism by which DCAF16 recruits neosubstrates through covalent modification.

Substrate recruitment by DCAF16 depends on covalent modification of cysteine residues on its surface. Studies using CRISPR screening and cryo-electron microscopy structural analysis revealed that SMARCA2/4 degraders recruit SMARCA2 by covalently binding to the C173 site of DCAF16. In addition to the covalent bond, the degrader forms extensive direct interactions with DCAF16: the pyridyl group of the degrader stacks with W181 of DCAF16, and the terminal azepane ring is embedded in a pocket jointly defined by Q1411-L1412 of the SMARCA2 BD, P170-S172 of the DCAF16 loop, and Y62 of DCAF16. In addition, the ternary complex interface forms numerous induced protein-protein contacts, including a hydrogen bond between the side-chain carboxyl group of SMARCA2 E1407 and the backbone amide of DCAF16 V174, as well as a hydrogen-bond network between residues of the BC loop of the SMARCA2 BD and the R191-I195 loop of DCAF16; these contacts together bury an interface area of approximately 1057 Å². Different degraders show differences in cysteine site preference: the original extended fumaramide handle mainly targets C173, whereas the truncated handle can target both C173 and C178. This spatial and structural tunability enables DCAF16 to accommodate a more diverse range of neosubstrates.

III. Modular applications of DCAF16 in targeted protein degradation.

DCAF16 has become a highly attractive E3 ligase in the field of covalent targeted degradation, and its applications have expanded from the initial degradation of BRD4 to multiple protein classes. Covalent degradation handles based on DCAF16 can be transplanted onto various target protein ligands to induce the degradation of CDK4, the androgen receptor, BTK, SMARCA2/4, and BCR-ABL/c-ABL. In the field of molecular glues, DCAF16 also demonstrates unique value: through a template-assisted covalent modification mechanism, the complex formed by the BD2 domain of BRD4 and DCAF16 can serve as a structural scaffold, directing the reactive moiety of a small molecule to a specific site on DCAF16 for covalent modification, thereby achieving highly selective degradation of BRD4. This concept of "template-assisted covalent modification" provides a new theoretical framework for the design of molecular glue degraders. In addition, DCAF16 has also been used in the development of covalent molecular glues targeting histone deacetylases (HDACs), achieving efficient degradation of HDAC1 in myeloma cells.

IV. Translational potential of DCAF16 as a therapeutic target for triple-negative breast cancer.

At the translational medicine level, DCAF16-based PROTACs have shown potential for treating triple-negative breast cancer. Researchers designed a DCAF16-based PROTAC targeting CDK4/6 (compound A4). This molecule can both inhibit CDK4/6 kinase activity and reduce CDK4/6 protein levels through a proteasome-dependent pathway in a concentration- and time-dependent manner. Notably, compound A4 is 7-fold less toxic in non-tumor cells than palbociclib, and it exhibits antitumor activity in both triple-negative breast cancer cell lines and triple-negative breast cancer xenograft mouse models. This result suggests that DCAF16-mediated degradation strategies may improve the therapeutic window while maintaining efficacy, providing a new intervention approach for triple-negative breast cancer, a subtype lacking targeted treatment options.

V. Conclusion.

As a structurally unique, cysteine-rich substrate receptor within the CUL4-DDB1 E3 ligase complex, DCAF16 has become a highly promising E3 ligase choice in the field of targeted protein degradation after CRBN and VHL, owing to its molecular mechanism of recruiting multiple neosubstrates such as BRD4, SMARCA2/4, CDK4/6, and the androgen receptor through covalent modification of sites including C173 and C178, as well as its modular feature as a transplantable covalent degradation handle platform.

In DCAF16-related basic research and targeted degradation drug development, high-quality recombinant DCAF16/DDB1 complex protein is a core tool for dissecting its substrate receptor function, evaluating degrader binding activity, and conducting ternary complex formation analysis. The His tag facilitates efficient purification via immobilized metal affinity chromatography and enables detection and capture with anti-His tag antibodies. To meet the needs of DCAF16 functional research and targeted protein degradation drug development, Univ provides DCAF16/DDB1 His Tag Protein, Human. This product is suitable for applications such as binding activity analysis of the DCAF16/DDB1 complex with covalent degradation handles, research on the mechanism of DCAF16-mediated recruitment of substrates such as BRD4 and SMARCA2/4, evaluation of ternary complex formation by PROTAC and molecular glue degraders, and development of DCAF16-based targeted degradation strategies.

This article is reviewed and published by the technical expert team of UA

Disclaimer: This article partially utilizes artificial intelligence assistance in its creation. If any content involves copyright or intellectual property issues, please let us know and we promise to verify and remove it as soon as possible.

Purchase recombinant protein, choose

UA protein focuses on providing various protein reagents, raw materials, and services required for drug research and development, cell therapy, gene therapy, and basic scientific research, including drug target proteins, immune checkpoint proteins, cytokines, tool enzymes, customized protein expression, and full-length transmembrane protein development. Nanjing Univ is committed to providing customers with high-quality products and professional services, and building a High-tech Biological Enterprise with International Competitiveness.

Buy antibodiesFind UA www.ua-bio.com | 15 years of protein development experience

Nanjing UNIV Biotechnology Co., Ltd. Email：order@ua-bio.com Phone：+86-25-56221161

more products

Product Information

The Last The Next